INCHEON, South Korea, Feb. 5 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) and Celltrion, Inc., a South Korean biopharmaceutical company, have signed a Letter of Intent to permit joint research on the development of novel antibodies to protect people exposed to the rabies virus.
Medical attention for a person exposed to rabies is a two-step procedure. First, rabies immune globulin (RIG) is given to provide immediate antibodies neutralizing the rabies virus. Thereafter, the patient receives five doses of vaccine to build active immunity against the rabies virus.
Active immunity is detectable after the first week of vaccination so RIG is essential at the first stage of medical attention before a person develops their own antibodies from vaccine.
There are currently two types of RIG: human and equine. Human RIG can sometimes be in short supply due to manufacturing restrictions. It is expensive, and there are regulatory concerns because it comes from human blood. Because equine RIG is derived from horses, there are concerns that it may not provide the proper antibody response, and there are international animal care and use issues because of the involvement of horses in its production. In developing countries, where the majority of human rabies cases occur, both types of RIG are frequently unavailable.
The CDC/Celltrion collaboration addresses these problems by using cell culture to manufacture RIG of a new generation, which is expected to be safer, more effective and affordable.
"The CDC is excited to begin a novel research collaboration with Celltrion on the development of additional products that can provide immunity to rabies. We believe this effort holds great public health promise toward the prevention of this deadly disease, especially in developing countries," said Charles E. Rupprecht, V.M.D., chief of the CDC's Rabies Program.
Rabies is a viral disease of mammals which is transmitted through the bite of infected animals. The virus infects the central nervous system, causing inflammation of the brain and ultimately death, if medical assistance is not sought promptly after the exposure to prevent the disease. Rabies is particularly prevalent in Eastern Europe, Asia, South America, and Africa. An estimated 40,000 to 70,000 people die of the disease each year, mainly in Asia and Africa.
About Celltrion: Celltrion, established in 2002, is a contract manufacturing organization with its headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products in order to develop into a fully integrated biotechnology company. For more information, please visit Celltrion's website at http://www.celltrion.com.
For additional information, please contact: Seung-Suh (Stanley) Hong, Ph.D. Senior Vice President, Business Development Celltrion, Inc. (USA) E-mail: firstname.lastname@example.org Tel: +1-650-766-2307
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of Celltrion as of the date of this release. These forward- looking statements are no guarantees for future performance, and the forward- looking events discussed in this press release may not occur. Celltrion disclaims any intent or obligation to update any of these forward-looking statements.
|SOURCE Celltrion, Inc.|
Copyright©2009 PR Newswire.
All rights reserved